HHMI
TEVA icon

Howard Hughes Medical Institute’s Teva Pharmaceuticals TEVA Stock Holding History

Howard Hughes Medical Institute’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-125,000
Closed -$4.15M – 110
2017
Q2 		$4.15M Hold
125,000
– – 0.76% 33
2017
Q1 		$4.01M Sell
125,000
-34,666
-22% -$1.18M 0.74% 33
2016
Q4 		$5.79M Buy
159,666
+118,385
+287% +$4.73M 1.32% 18
2016
Q3 		$1.9M Sell
41,281
-8,181
-17% -$427K 0.49% 51
2016
Q2 		$2.48M Buy
49,462
+14,313
+41% +$762K 0.83% 42
2016
Q1 		$1.88M Buy
35,149
+23,544
+203% +$1.38M 0.41% 52
2015
Q4 		$762K Buy
+11,605
New +$717K 0.12% 81
2015
Q3 		– Sell
-339
Closed -$20K – 178
2015
Q2 		$20K Buy
+339
New +$20.9K ﹤0.01% 157

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Howard Hughes Medical Institute's TEVA Position: Q3 2017 in Review

Howard Hughes Medical Institute sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 125,000 shares — an estimated $4.15M sold.

Howard Hughes Medical Institute first reported a position in TEVA in Q2 2015 and held it in 8 quarters. The position peaked at $5.79M in Q4 2016. 536 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • Howard Hughes Medical Institute reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Howard Hughes Medical Institute sold 125,000 Teva Pharmaceuticals shares in Q3 2017, an estimated $4.15M.
  • Howard Hughes Medical Institute first reported a position in Teva Pharmaceuticals in Q2 2015 and held it in 8 quarters.
  • Howard Hughes Medical Institute's Teva Pharmaceuticals position peaked at $5.79M in Q4 2016.
  • 536 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Howard Hughes Medical Institute's 13F filing for Q3 2017, filed 2 Nov 2017.